Share on Google Plus Share on Twitter Share on Facebook 1 Share on LinkedIn Share on PInterest Share on Fark! Share on Reddit Share on StumbleUpon Tell A Friend (1 Shares)  
Printer Friendly Page Save As Favorite View Favorites View Stats   1 comment

Exclusive to OpEdNews:
General News

Gilead Sciences Under Investigation for Over-Charging for Hepatitis C Pill

By (about the author)     Permalink       (Page 1 of 1 pages)
Related Topic(s): ; ; ; ; ; , Add Tags Add to My Group(s)

Well Said 1   News 1   Supported 1  
View Ratings | Rate It

opednews.com Headlined to H4 7/21/14


How much should we pay for medicine?
(image by Corpwatch)


Reprinted from corpwatch.org

Gilead Sciences of San Francisco is under investigation by the U.S. Senate Finance Committee for charging $84,000 for a 12 week course of a new drug to treat hepatitis C. Gilead sells the exact same course for $900 in poor countries like Egypt and India.

Sovaldi - the brand name for sofosbuvir - was approved last December by the U.S. Food and Drug Administration, to treat hepatitis C, a viral infection that can cause fever, fatigue, cirrhosis and deadly liver cancer. Some 150 million people around the world are estimated to be at risk, often many years after receiving contaminated blood tranfusions. (Body Shop founder Anita Roddick died from such a transfusion). Solvaldi has been described as a breakthrough drug because of its ability to cure victims in just three months, with few side effects.

A new study by Express Scripts, a pharmacy benefits firm, estimates that U.S. government healthcare programs alone will have to spend $55 billion to buy Sovaldi. "Should the states be compelled to pay for everyone?" Dr. Steve Miller, medical director for the firm, asked NBC News. "You're going to have to figure out if you're going to have to go back to your voters and ask for more funding."

"Although Sovaldi has the potential to help people with HCV, at $1,000 per pill, its pricing has raised serious concerns about the extent to which the market for this drug is operating efficiently and rationally," the senators wrote. "Given the impact Sovaldi's cost will have on Medicare, Medicaid and other federal spending, we need a better understanding of how your company arrived at the price for this drug."

Activists have been sharply critical. Jennifer Cohn of Doctors Without Borders described Gilead's prices as "corporate greed."


The critics point in particular to the fact that Gilead has agreed to sell the same drug in the U.K. for $57,000 a course, after the government-run National Health Service negotiated lower prices with the company and for just $900 in Egypt."Egypt's example shows the power of a public health approach and its large scale," Stefan Wiktor, the director of the World Health Organization's global hepatitis program, told Bloomberg. "One of the reasons they were able to negotiate a lower price is because they have a big program."

The company defends its pricing policy. "Gilead's global pricing model is based on a country's ability to pay," says Gregg Alton, executive vice president of corporate and medical affairs at Gilead.

Yet, Gilead's strategy is also likely based on the fact that poor countries like India have taken a firm stand against paying astronomical prices for specialized drugs and courts have ruled in their favor a number of times. Instead of fighting the matter in the courts like Novartis, Gilead has taken a more practical approach of sitting down at the bargaining table. The problem for U.S. victims is that once private health insurers have agreed to pay top dollar, it raises the price for others in the same country, notably the state insurance programs.

Experts say that astronomical prices for newly patented "breakthrough" drugs are not going away anytime soon so long as U.S. insurance companies are willing to pay, a prospect that has helped the stock prices of pharmaceutical companies to soar. For example, Kalydeco, a new drug to treat cystic fibrosis, a genetic lung disease, is priced at $300,000 a year for a treatment that last for a lifetime.

"Wall Street is all charged up. There really hasn't been any pushback yet on cost," Barry Werth, the author of "The Antidote," a book about Kalydeco, told the New York Times. When asked why the company charged so much for the drug, Werth said simply: "Because they can."

 

http://www.corpwatch.org/index.php

CorpWatch: Non-profit investigative research and journalism to expose corporate malfeasance and to advocate for multinational corporate accountability and transparency. We work to foster global justice, independent media activism and democratic control over corporations.

We seek to expose multinational corporations that profit from war, fraud, environmental, human rights and other abuses, and to provide critical information to foster a more informed public and an effective democracy.

Click here for our 2010-2011 Combined Report
Click here for our 2007-2009 Combined Report
Click here for our 2006 Annual Report
Click here for our 2005 Annual report
Click here for our 2004 Annual report

Our guiding vision is to promote human, environmental, social and worker rights at the local, national and global levels by making corporate practices more transparent and holding corporations accountable for their actions.

As independent investigative researchers and journalists, we provide critical information to foster a more informed public and an effective democracy.

We believe the actions, decisions, and policies undertaken and pursued by private corporations have very real impact on public life -- from individuals to communities around the world. Yet few mechanisms currently exist to hold them accountable for those actions. As a result, it falls to the public sphere to protect the public interest.

In many cases, corporate power and influence eclipses even the democratic
political process itself as they exert disproportional influence on public policy they deem detrimental to their narrow self-interests. In less developed nations, they usurp authority altogether, often purchasing government complicity for unfair practices at the expense of economic, environmental, human, labor and social rights. 

Yet despite the very public impact of their actions and decisions, corporations remain bound to be accountable solely to their own private financial considerations and the interests of their shareholders. They have little incentive, nor requirement, for public transparency regarding their decisions and practices, let alone concrete accountability for their ultimate impact.



Share on Google Plus Submit to Twitter Add this Page to Facebook! Share on LinkedIn Pin It! Add this Page to Fark! Submit to Reddit Submit to Stumble Upon

Go To Commenting
The views expressed in this article are the sole responsibility of the author and do not necessarily reflect those of this website or its editors.

Writers Guidelines

Contact Author Contact Editor View Authors' Articles

Most Popular Articles by this Author:     (View All Most Popular Articles by this Author)

Boeing Helps Kill Proposed Law to Regulate Drones

H&M Responds Slowly to Bangladesh Factory Collapse Killing 1,100

ACLU Reveals FBI Hacking Contractors

Hedge Fund Managers Still Making Billions

CorpWatch : Commodity Scams: Barclays, Goldman & JP Morgan Under Fire

CorpWatch : GlaxoSmithKline Alleged to Pay Bribes in China

Comments

The time limit for entering new comments on this article has expired.

This limit can be removed. Our paid membership program is designed to give you many benefits, such as removing this time limit. To learn more, please click here.

Comments: Expand   Shrink   Hide  
1 people are discussing this page, with 1 comments
To view all comments:
Expand Comments
(Or you can set your preferences to show all comments, always)

Very wrong and ignorant article, as is the investi... by BFalcon on Tuesday, Jul 22, 2014 at 9:41:37 AM